Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 5/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.34 |
| ▸ | CPA1 | P15085 | 2/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6009571 | 1.00 | RNPEP (0.36) | RNPEPSLC7A5MMESLC1A3SLC1A2 | |
| SCHEMBL6275148 | 0.86 | OR51E2 (0.36) | ALDH1A1OR51E2LMNA | |
| SCHEMBL6275155 | 0.86 | OR51E2 (0.36) | ALDH1A1OR51E2LMNA | |
| SCHEMBL28678140 | 0.82 | RNPEP (0.34) | RNPEPSLC7A5MMESLC1A3SLC1A2 | |
| SCHEMBL6010151 | 0.82 | OR51E2 (0.39) | ALDH1A1OR51E2LMNA | |
| SCHEMBL6010163 | 0.82 | OR51E2 (0.39) | ALDH1A1OR51E2LMNA | |
| SCHEMBL14906341 | 0.77 | GPR84 (0.47) | SLC1A2SLC1A1MAPT | |
| SCHEMBL7777306 | 0.77 | SLC22A6 (0.41) | MAPTALDH1A1OR51E2LMNA | |
| SCHEMBL6010347 | 0.76 | OR51E2 (0.37) | ALDH1A1OR51E2TP53LMNA | |
| SCHEMBL6010362 | 0.76 | OR51E2 (0.37) | ALDH1A1OR51E2TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | SEIWA KASEI COMPANY, LIMITED (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1584320-A1 | COSMETIC PREPARATION CONTAINING GLYCERYLAMINO ACID DERIVATIVE | Seiwa Kasei Company, Limited (JP) | 2005-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | GLA, GPKOW, CUTA | RNPEP 2950/4885SLC7A5 1780/4885MME 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.